NCT03062059 - The Effectiveness and Safety of Intravesical Gemcitabine Instillation to Prevent Intravesical Recurrence | Biotech Hunter

Enrollment

134

Participants

Timeline

Start Date

March 1, 2018

Primary Completion Date

December 31, 2022

Study Completion Date

December 31, 2022

Conditions

Urothelial Carcinoma

Interventions

DRUG

Intravesical 2000mg/52.6ml gemcitabine instillation

Intravesical 2000mg/52.6ml gemcitabine instillation during operation to prevent intravesical recurrence after radical nephroureterectomy in upper urinary tract urothelial carcinoma

OTHER

Normal saline

Intravesical 52.6ml normal saline instillation after radical nephroureterectomy in upper urinary tract urothelial carcinoma

Trial Locations (5)

Unknown

RECRUITING

National Cancer Center, Goyang

RECRUITING

Asan Medical Center, Seoul

RECRUITING

Korea University Anam Hospital, Seoul

RECRUITING

Samsung Medical Center, Seoul

RECRUITING

Seoul National University Hospital, Seoul